Navigation Links
Ambrx Enters FGF-21 Type 2 Diabetes Drug Discovery Collaboration with Merck and Co. Inc.
Date:12/18/2007

SAN DIEGO, Dec. 18 /PRNewswire/ -- Ambrx Inc. today announced that it has entered into a global, strategic collaboration with Merck & Co. Inc. to develop a novel therapeutic protein with biological properties similar to Fibroblast Growth Factor 21 (FGF-21) for the treatment of type 2 diabetes and related metabolic disorders such as obesity.

The collaboration utilizes Ambrx's proprietary protein technology, ReCODE(TM), to develop a chemically modified and optimized drug candidate designed to have improved therapeutic properties over the native FGF-21 protein.

"We are pleased to enter into this agreement with Merck, a world leader in the metabolic diseases field with a proven track record in the rapid development and launch of diabetes medicines," said Stephen W. Kaldor, Ph.D., Ambrx's president and chief executive officer. "We are excited about the potential of our initial FGF-21 protein drug candidates, as they promise unique pharmacological efficacy in the treatment of diabetes, a disease of large and rapidly increasing prevalence."

"Molecules capable of mimicking the biological properties of the natural protein FGF-21 represent promising candidates for the treatment of metabolic disorders such as type 2 diabetes and obesity," said Luciano Rossetti, M.D., senior vice president and franchise head, Diabetes/Obesity and Cardiovascular Franchises at Merck. "Ambrx has developed several novel preclinical protein therapeutic candidates designed to provide enhanced therapeutic properties that may complement our portfolio of products for people with metabolic disorders."

The transaction includes an initial upfront payment in addition to committed R&D payments. Ambrx will also be eligible to receive future milestone payments associated with research, development and commercialization of a drug candidate resulting from the collaboration along with royalties on net sales. Ambrx also has the right to exercise an "end of Phase II" profit sharing option. Additional terms of the agreement were not disclosed. It is expected that this collaboration, in conjunction with three others announced this year, will preclude the necessity for Ambrx to raise additional equity capital for a number of years.

About Ambrx

Ambrx Inc. is a biopharmaceutical company focused on the discovery and development of first-in-class and best-in-class BioSuperior(TM), protein-based drugs. Using its technology, the company can overcome the performance limitations of high-value commercial proteins by improving their efficacy, safety and ease of use. Ambrx's core ReCODE(TM) technology enables the precise, site-specific substitution of a novel amino acid within a protein. This allows the conjugation of proteins with additional molecules that can serve to modulate their pharmacokinetic profile or biological function. Ambrx's ReCODE(TM) technology is applicable to multiple protein products across numerous therapeutic areas. Ambrx has successfully and rapidly applied its innovative technology platform to advance into the clinic with ARX201, its first proprietary molecule, and is building a broad pipeline of additional product opportunities. For additional information, call 858.875.2400 or visit http://www.ambrx.com.


'/>"/>
SOURCE Ambrx Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
2. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
3. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
4. Cepheid Announces Termination of Contract With the Centers for Disease Control and Prevention to Develop Rapid Point of Care Test for Avian Influenza
5. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers
6. Concentra Medical Centers Gears Up for Flu Season to Keep Area Workforce Healthy
7. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
8. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
9. Isis Initiates Phase 1 Study of ISIS 325568 Targeting Glucagon Receptor to Treat Type 2 Diabetes
10. Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells
11. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/11/2018)... , ... August 10, 2018 , ... US Capital ... following a $2 million seed funding round. Carepoynt is an emerging leader in the ... center of a more rewarding and engaging healthcare ecosystem. , Headquartered in San Francisco, ...
(Date:8/9/2018)... ... 2018 , ... Autism is a developmental disorder affecting more than 3.5 million ... 1 in 68 people have the disorder), chances are you know someone on the ... child with autism methods of communication and tactics to interact with others. These options ...
(Date:8/7/2018)... ... 07, 2018 , ... Commissioner Gottlieb’s FDA:, Analysis of First Year and a ... ET, http://www.fdanews.com/commissionergottliebsfda , Under Commissioner Scott Gottlieb, changes at the FDA ... may have gotten hurt. , And Gottlieb is just getting started. , Mark the ...
Breaking Medicine Technology:
(Date:8/14/2018)... (PRWEB) , ... August 14, 2018 , ... Ross A. ... generation of freezing fat, at Clevens Face and Body Specialists. Dr. Clevens is known ... patients at his Melbourne and Merritt Island offices. Along with his associate, Amy Simon, ...
(Date:8/11/2018)... , ... August 10, 2018 , ... ... leader in Gout Relief. , What is gout? This painful, persistent condition originates ... a result of high levels of uric acid. Other contributing factors may be ...
(Date:8/11/2018)... Ga. (PRWEB) , ... August 10, 2018 , ... ... is known for providing innovative procedures to metro Atlanta. Drs. Brent Sharpe and ... at Northeast Georgia Medical Center in Braselton. , On June 27, the physicians ...
(Date:8/9/2018)... (PRWEB) , ... August 09, 2018 , ... ... not realize their implants have ruptured, according to cross-referenced data from The American ... and silicone gel implant rupture rates monitored by the FDA. As an MRI ...
(Date:8/9/2018)... ... August 09, 2018 , ... Balboa Horizons, ... new verification process that substance abuse providers must pass in order to advertise ... reach more people to help.” , Helping people is what Balboa Horizons ...
Breaking Medicine News(10 mins):